Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Responses to COVID-19 vaccination in patients with CLL

Yair Herishanu • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia Antibodies BTK inhibitors

Yair Herishanu, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, comments on the increased risk of infection-related mortality in patients with chronic lymphocytic leukemia (CLL) affected by COVID-19, discussing humoral and T-cell responses to COVID-19 vaccination in these patients. Dr Herishanu explains that response to vaccines in these patients is lower than that of the general population and depends on their current treatment. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yair Herishanu

1:54
Preventing severe COVID-19 infection in patients with CLL
Yair Herishanu • 7 Oct 2022

Related Videos

6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
1:56
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
Dima El-Sharkawi • 28 Apr 2024
1:17
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Thomas Coats • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals